Article,
A Review of Telmisartan Angiotensin II Receptor Blocker Treatment of Hypertension
INTERNATIONAL JOURNAL OF TREND IN SCIENTIFIC RESEARCH AND DEVELOPMENT, 7 (6): 393-401 (December 2023)
Abstract
Telmisartan, a long acting antihypertensive agent is essential to achieve blood pressure control in the early morning due to its terminal elimination half life of 24hrs and has a large volume of distribution. According to CBS classification it belongs to class II i.e. low solubility and high permeability. High volume of distribution coupled with high lipophilicity is the unique feature of angiotensin II receptor blocker, it offers the clinical advantage of good tissue penetration. It particularly blocks the angiotensin II receptor without blocking other receptors which are involved in cardiovascular regulation. According to recent data telmisartan 80mg controls early morning blood pressure more effectively than ramipril 5 10mg and has greater effect over cardiovascular risk. It is also more effective than losartan and in addition, angiotensin II blocker provides superior blood pressure control after a missed dose compared with valsartan 80mg. Tejaswini Kande | Mr. Laukik Raskar | Mr. Bharat Rathod | Srushti Rajpurohit | Shreya Salunke | Ms. Shubhangi Karkhile Ä Review of Telmisartan Angiotensin II Receptor Blocker: Treatment of Hypertension" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-7 | Issue-6 , December 2023, URL: https://www.ijtsrd.com/papers/ijtsrd61199.pdf Paper Url: https://www.ijtsrd.com/pharmacy/analytical-chemistry/61199/a-review-of-telmisartan-angiotensin-ii-receptor-blocker-treatment-of-hypertension/tejaswini-kande
